Recursion Pharmaceuticals, Inc. (RXRX) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
RXRX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 6, 2026, Recursion Pharmaceuticals, Inc. (RXRX) trades at a price-to-earnings ratio of -2.4x, with a stock price of $3.43 and trailing twelve-month earnings per share of $-1.06.
Compared to the Healthcare sector median P/E of 22.1x, RXRX trades at a 111% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, RXRX trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RXRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
RXRX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.8Lowest | 0.66 | +817%Best | |
| $5.0T | 42.4 | 0.44Best | +67% | |
| $22B | 26.2 | 6.18 | +171% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See RXRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RXRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RXRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRXRX — Frequently Asked Questions
Quick answers to the most common questions about buying RXRX stock.
Is RXRX stock overvalued or undervalued?
RXRX current P/E: -2.4x. 5-year average P/E: N/A. Percentile: N/A.
How does RXRX's valuation compare to peers?
Recursion Pharmaceuticals, Inc. P/E of -2.4x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is RXRX's PEG ratio?
RXRX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.